US court delays Novartis/Sandoz biosimilar Zarxio's marketing
This article was originally published in Scrip
Executive Summary
Amgen won its motion for an injunction to stop Novartis and its Sandoz unit from putting their newly approved biosimilar Zarxio (filgrastim-sndz) on the market until the US Court of Appeals for the Federal Circuit renders a decision in an ongoing lawsuit.